1 2	Association between Time-Weighted Remnant Cholesterol and Incident Cancer: A Population- Based Chinese Cohort Study
3	Lifang Li PhD *1,2 Nan Zhang BSc *3 Vifan Vang PhD 4 Hugo Hok Him Pui ⁵ Bosco Kwok Hei Leung ⁵
4 5	Oscar Hou In Chou MSc ⁶ Carlin Chang MBChB MPhil MBCP EHKAM ⁶ Abraham Ka Chung Wai
6	MBChB MD ERCEM ERCP ⁵ Gregory Lin MD ERCP EESC EACC ⁷ Gary Tse DM PhD ERCP EEPH ^{1,2,3}
7	Tong Liu MD PhD ^{-,3} Jiandong Zhou PhD ^{-,8,9, 10, 11}
8	
9	¹ School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong SAR, China
10	² Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute,
11	Hong Kong SAR, China
12	³ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
13 14	Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
15	⁴ School of Management, Xi'an Jiaotong University, Xi'an, China
16	⁵ Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
17	Kong SAR, China
18	⁶ Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
19	⁷ Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores
20	University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Danish Center for
21	Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
22	⁸ Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University
23	of Hong Kong, Hong Kong SAR, China
24	⁹ School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
25	SAR, China
26	¹⁰ Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong SAR, China
27	¹¹ Division of Health Science, Warwick Medical School, University of Warwick, Coventry, United
28	Kingdom
29	
30	* Contributed equally
31	^ Correspondence to:
32	Tong Liu PhD,
33	Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
34	Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin
35	300211, China
36	Email: <u>liutongdoc@126.com</u>
37	Prof. Jiandong Zhou, PhD
38	Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of
39	Medicine, The University of Hong Kong, Hong Kong, China
40	School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,
41	China
42	Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong SAR, China
43	Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom
44	Email: jdzhou@hku.hk, jiandong.zhou@warwick.ac.uk
45	Study category. Uriginal Article

46 Abstract

Background: Remnant cholesterol (RC) is becoming an increasingly well-recognized risk factor for cardiometabolic diseases. However, no study has explored the predictive role of RC in new-onset cancer. This study aimed to examine the associations between RC and time-weighted RC with incident cancer in the general population.

51 **Methods**: This was a retrospective population-based study enrolling patients attending family 52 medicine clinics in Hong Kong between 1st January 2000 and 31st December 2003 with at least three 53 RC measurements during follow-up visits. The primary outcome was new-onset cancer. The secondary 54 outcome was cancer-related mortality. Multivariable Cox regression was used to evaluate 55 associations between baseline RC and time-weighted RC with outcomes.

Results: A total of 75,342 adults (39.7% males, mean age: 62.5 years old) were included. During a 56 57 median follow-up of 16.8 years, 8335 (11.1%) incident cancer and 4349 (5.7%) cancer-related deaths were observed. After adjusting for potential confounders, one mmol/L increased of time-weighted 58 RC was associated with 41% and 62% higher risk of incident cancer (HR, 1.41; 95%CI, 1.26-1.57; 59 60 p<0.0001) and cancer-related mortality (HR, 1.62; 95%CI, 1.43-1.85; p<0.0001), respectively. However, no significant association between baseline RC with risk of new-onset cancer (HR, 1.04; 95%CI, 0.82-61 1.31; p=0.768) and cancer-related mortality (HR, 0.85; 95%CI, 0.61-1.17; p=0.315) in the adjusted 62 63 model. The association between time-weighted RC and incident cancer was significant regardless of age, gender, and remained consistent amongst those with baseline use of most cardiometabolic 64 agents, as well as those complicated with most comorbidities. 65

66 Conclusions: Higher time-weighted RC was associated with increased risk of new-onset cancer and
 67 cancer-related mortality amongst the general population.

Keywords: Cancer, Low-density lipoprotein, Very-low-density lipoprotein, Intermediate-density
 lipoprotein, Remnant cholesterol.

70 Word count: 2837 (Including sections from Introduction to Conclusion)

71 Introduction

The growing global burden of cancer is rapidly exceeding the current cancer control capacity. Worldwide, an estimated 28.4 million new cancer cases are projected to occur in 2040, a 47% increase from the corresponding 19.3 million cases in 2020. Additionally, cancer has ranked as a leading cause of death, with expected 16 million deaths from cancer in 2040 globally.¹ Therefore, it is of utmost importance to develop effective preventive strategies to facilitate global cancer control, which requires identification of potentially modifiable risk factors and determination of their contribution to cancer burden.²

79 Dyslipidemia has been considered as an important risk factor for cancer. However, previous studies regarding the association between dyslipidemia with cancer have mainly focused on other 80 lipid profiles, such as LDL and triglyceride.^{3, 4} Remnant cholesterol (RC), also called triglyceride-rich 81 82 lipoprotein (TRL) cholesterol, which comprises cholesterol carried in very-low-density lipoproteins (VLDL), chylomicron remnants, and intermediate-density lipoproteins, has been increasingly 83 acknowledged as an important risk factor for several burdensome diseases, such as atherosclerotic 84 cardiovascular disease (ASCVD),⁵ diabetes,⁶ and nonalcoholic fatty liver disease.⁷ However, as a highly 85 burdensome disease, so far, no study has investigated the role of RC in the development of cancer. 86 Therefore, this study aimed to examine the associations between RC level and incident cancer in the 87 general population. Besides, to provide a dynamic picture of RC's long-term effects, this study also 88 89 focused on the associations between time-weighted RC with new-onset cancer.

90

91 Methods

This retrospective study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (Reference No. UW 20-250) and complied with the Declaration of Helsinki. Due to the retrospective design and use of deidentified data, the need for patient consent was waived.

96 Data source

97 Data were acquired from the Clinical Data Analysis Reporting System (CDARS) of the Hong Kong

Hospital Authority, a statutory body that manages all public hospitals and their affiliated outpatient 98 and day care facilities in Hong Kong, covering approximately 90% of the population and being the 99 most representative electronic medical database available in Hong Kong.⁸ CDARS prospectively 100 collects patient information including, but not limited to, demographic data, selected laboratory tests, 101 diagnoses, drug prescriptions, procedures, and episodes of hospital visits since 1993. CDARS encodes 102 diagnoses using the International Classification of Diseases, ninth revision (ICD-9), as CDARS has not 103 implemented ICD-10 codes to date.⁹ Mortality data were acquired from the linked Hong Kong Death 104 105 Registry, a governmental registry of mortality data for Hong Kong citizens. CDARS and the linked Hong Kong Death Registry have been used extensively in research, with good coding accuracy and data 106 completeness as demonstrated in previous studies.^{10, 11} 107

108

109 Study population

Patients aged 18 years old or above, without prior cancer history, who attended a family medicine clinic in Hong Kong between 1st Jan 2000 and 31st December 2003 were included. Those without baseline RC data and at least three valid RC tests during follow-up visits were excluded.

113

114 Follow-up and Outcomes

All patients were followed up until 31st December 2019. The primary outcome of this study was new-onset cancer. The secondary outcome was cancer morality. ICD-9 codes for identifying sitespecific cancer were listed in **Supplemental Table 1**.

118 Data collection

The following data at baseline were collected: age, gender, Charlson's comorbidity index, prior comorbidities, medication prescriptions, and selected laboratory results (kidney function, liver function, glucose and lipid profiles). All comorbidities were identified using ICD-9 codes, which were listed in **Supplemental Table 1**. Baseline and variability measures of blood pressure, glucose and lipid profiles were presented. Variability profiles were evaluated by SD and time-weighted measures. The following formula, $\sqrt{\frac{1}{n-1}\sum_{i=1}^{n}(x_i-\bar{x})^2}$, was used to calculated SD. Time-weighted measures was computed by the products of the sums of three consecutive measurements and the time interval, then divided by the total time interval.¹² In addition, RC was calculated by total cholesterol minus LDL-C minus HDL-cholesterol (HDL-C).¹³ Besides, some calculated biomarkers, including the estimated glomerular filtration rate based on the abbreviated modification of diet in renal disease (AMDRD) formula,¹⁴ neutrophil-to-lymphocyte ratio (NLR),¹⁵ and triglyceride-glucose index (TGI) were also presented.¹⁶

131 Statistical analysis

Descriptive statistics were used to summarize patients baseline clinical and biochemical 132 characteristics. Continuous variables were presented as mean ± standard deviation (SD) or median 133 with interquartile range (IQR) depending on their distribution. Categorical variables were presented 134 as frequencies and percentages. Baseline RC and RC variability were assessed as both quartiles and 135 continuous variable. Baseline characteristics of the included participants were compared according 136 to the quantiles of RC and time-weighted RC, respectively. Kaplan-Meier curves were used to visualize 137 138 the cumulative incidence of overall cancer and site-specific cancers across guartiles of baseline RC and time-weighted RC, respectively. Four separate Cox models were fitted hierarchically to estimate 139 the adjusted hazard ratio (HR) and 95% CI for the associations between RC and time-weighted RC 140 with outcomes. A priori subgroup analyses were performed using the fully adjusted Cox model with 141 RC and time-weighted RC measures as continuous variables, according to age, gender, prior 142 comorbidities, and medication prescriptions. 143

P value <0.05 was considered statistically significant. The statistical analysis was performed with
 RStudio software (Version 1.1.456) and Python (Version 3.6).

146 **Results**

Altogether, 155,066 patients were identified. After applying the exclusion criteria, 75,342 adult patients with available baseline RC result and at least three RC results during follow-up visits were included in the final analysis (29,905 male [39.7%]; median age 62.5 years [interquartile range 51.5, 71.4 years]) (**Figure 1**). The baseline characteristics of included patients by RC and RC variability

151 quartiles are summarized in **Table 1**.

During a median follow-up of 16.8 (14.4, 17.9) years, 8335 (11.1%) patients developed incident cancer and 4349 (5.7%) died from cancer. Among the incident cancer cases, gastrointestinal cancer (N=3790, 5.0%) represented the most common type, followed by genitourinary cancer (N=2117, 2.8%), colorectal cancer (N=2051, 2.7%) and other types (**Supplemental Table 3 and 4**). The median baseline RC and time weighted RC of the overall cohort was 0.6 (0.4, 1.0) mmol/L and 0.7 (0.5, 0.9) mmol/L, respectively (**Table 1**). The relationship between RC with time-weighted RC, HDL-C, LDL-C, total cholesterol, and triglyceride on incident cancer were illustrated in **Supplementary Figure 1**.

159 Association between baseline RC and outcomes

160 Cumulative incidence curves showed that groups with incrementally higher levels of remnant cholesterol had progressive higher incidences of overall cancer (Figure 2A). Table 2 summarizes 161 162 results of multivariable Cox regression models evaluating the associations between the RC level and the risk of incident cancer. After adjusting for demographics, comorbidities, medications, AMDRD, 163 NLR, TGI, baseline and variability of blood pressure, glucose and other lipid profiles, no significant 164 165 association was observed between baseline RC level with new-onset cancer (HR, 1.04; 95%CI, 0.82-1.31; p=0.768), or cancer-related mortality (HR, 0.85; 95%CI, 0.61-1.17; p=0.315). Results for the 166 associations between RC with individual cancer types after adjusting for confounders were also in line 167 168 with the primary analysis (Table 2; Supplemental Figure 2).

169 Association between time-weighted RC and outcomes

Cumulative incidence curves showed a significant association between higher RC variability with 170 increased risk of incident cancer (Figure 2B). In the fully adjusted model, one mmol/L increased of 171 172 time-weighted RC was associated with 41% and 62% higher risk of incident cancer (HR, 1.41; 95%Cl, 1.26-1.57; p<0.0001) and cancer-related mortality (HR, 1.62; 95%CI, 1.43-1.85; p<0.0001), 173 respectively. For individual cancer types, higher time-weighted RC was associated with significantly 174 increased risk of lung cancer (HR, 1.60, 95%CI, 1.28-2.00; p<0.0001), gastrointestinal cancer (HR, 1.39; 175 176 95%Cl, 1.18-1.64; p=0.0001), colorectal cancer (HR, 1.47; 95%Cl, 1.21-1.78; P=0.0001), ovarian cancer (HR, 2.707; 95%CI, 1.231-5.954; P=0.0133), and genitourinary cancer (HR, 1.27; 95%CI, 1.00-1.61; 177 p=0.0483), but not for breast cancer (HR, 1.12; 95%CI 0.74-1.70; p=0.5904), prostate cancer (HR, 1.27; 178

95%Cl, 0.91-1.77; p=0.1682), pancreatic cancer (HR, 0.45; 95%Cl, 0.09-2.39; p=0.3512), liver cancer
(HR, 0.86; 95%Cl, 0.38-1.95; p=0.7213), or bladder cancer (HR, 0.73; 95%Cl, 0.31-1.73; p=0.4705)
(Table 2; Supplemental Figure 3).

182

183 *Subgroup analyses*

Subgroup analyses identified a significant association between time-weighted RC and incident cancer both in females (HR 1.07; 95% CI 1.03-1.11; P=0.001) and males (HR 1.10; 95% CI 1.06-1.15; P<0.001) (**Figure 3**). In subgroup analysis by age, the association between time-weighted RC and cancer was significant among both the younger (<65 years, HR 1.07; 95% CI 1.01-1.12; P=0.013) and older (>65 years, HR 1.05; 95% CI 1.02-1.09; P = 0.004) individuals (**Figure 3**).

189 Further analyses were performed according to prior comorbidities, which suggested a significant association between time-weighted RC and cancer regardless of the presence of baseline 190 dyslipidemia, diabetes mellitus, ischemic heart disease, and liver disease (Figure 3). However, the 191 192 association between time-weighted RC with cancer was more prominent among those complicated 193 with baseline hypertension (HR, 1.19; 95%Cl 1.15-1.23; P<0.001), but not for those without (HR, 1.01; 194 95%CI 0.96-1.05; P=0.812), with a P for interaction < 0.001. In subgroup analyses according to medication use, higher time-weighted RC was consistently associated with increased risk of cancer, 195 regardless of the baseline usage of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin 196 receptor blocker (ARB), beta-blockers, antiplatelets, statins and fibrates, overall lipid-lowering drugs, 197 198 and non-steroidal anti-inflammatory agents. Compared to patients treated with anti-diabetic drugs, 199 those without exposure to anti-diabetic drugs presented with a significant association between time-200 weighted RC with cancer (HR, 1.09; 95%Cl 1.06-1.13; P<0.001), whereas the interaction did not reach 201 the traditional significance (P for interaction=0.257) (Figure 3).

Results from subgroup analyses between RC and cancer were generally consistent with those observed between time-weighted RC with cancer (**Supplemental Figure 4**). Notably, higher RC level was associated with significantly increased risk of new-onset cancer in female individuals (HR 1.17; 95% CI 1.11-1.22; P<0.001), but not for male (HR 0.96; 95% CI 0.90-1.02; P=0.199), with a p for interaction < 0.001. Besides, Higher RC level was associated with significantly increased risk of cancer among those without medication history of statins and fibrates (HR, 1.10; 95%CI 1.06-1.15, p<0.001),

but not for those exposure to statins and fibrates (HR, 0.96; 95%Cl 0.88-1.05, p=0.363), with a p for interaction of 0.004.

210

211 Discussion

212 In this population-based cohort study with over 16 years of follow-up, several key findings were 213 noted. First, higher time-weighted RC, but not single time point RC, was significantly associated with 214 increased risks of new-onset cancer, especially for lung cancer, gastrointestinal cancer, genitourinary 215 cancer, and ovarian cancer. Second, the association between time-weighted RC and incident cancer was significant regardless of age and gender. The association remained consistent amongst those with 216 217 baseline use of most cardiometabolic agents, as well as those complicated with most comorbidities. 218 Last, higher time-weighted RC was associated with significantly increased risk of cancer-related mortality, but not for single RC measurement. To our knowledge, the present study is the first to 219 demonstrate the effects of RC and time-weighted RC in the development of cancer and cancer-related 220 221 mortality.

222 Comparison with previous studies

Previous preclinical studies have suggested a role of cholesterol in cancer, with several 223 224 demonstrating that cholesterol homeostasis genes can modulate cancer development.⁴ In addition, some epidemiologic studies also identified an association between higher serum cholesterol and LDL 225 level with increased risk of incident cancer.^{20, 21} In line with the prior studies, our study observed that 226 higher time-weighted RC was significantly associated with increased risk of new-onset cancer in the 227 228 general population, which adds to the existent evidence that time-weighted RC may be a potential tool for cancer risk assessment. In the present study, the predictive role of time-weighted RC was only 229 230 observed in lung cancer, colorectal cancer, ovarian cancer, overall gastrointestinal cancer and 231 genitourinary cancer. The discrepancy of the predictive role of lipid profile across various site-specific cancers has also been observed in other studies.²¹ Prior investigation has demonstrated that 232 intracellular cholesterol homeostasis varies among different cancer types,²² therefore, whether RC 233 234 plays differing roles in various cancer type needs further exploration. In addition, future large-scale 235 study to reveal the genetic architecture of RC and nonlinear Mendelian randomization study to 236 explore the causal association between RC and cancel are needed.

237 Though no study has addressed the association between RC and incident cancer, several observational studies have explored the relationship between RC and cancer-related mortality but 238 yielded controversial results. Both Wadström et al.²³ and Bonfiglio et al.²⁴ have focused on the 239 association between baseline RC levels with cancer mortality, whereas they failed to observe a 240 significant correlation. In agreement with Wadström et al.²³ and Bonfiglio et al.²⁴, no significant 241 association between baseline RC and cancer-related mortality was identified in the present study, 242 whereas we found a significant association between time-weighted RC with cancer-related mortality, 243 244 regardless of age, gender, and presence of most comorbidities and medication history. Time-weighted measurement, an index of homeostasis that takes into account the time spent at every single test, 245 has been demonstrated to be superior to and more robust than static indices.^{25, 26} Therefore, by using 246 the time-weighted measurement, our study could provide a dynamic picture of RC's homeostasis on 247 cancer risk and cancer mortality. Interestingly, in the study by Tian et al., during a median follow-up 248 of 3.6 years, an association between increased baseline RC and reduced risk of overall, liver and 249 stomach cancer-related morality was observed.²⁷ However, the prior study may be limited by the 250 relatively short follow-up and the possibility of reverse causation.²⁷ For example, liver cancer is usually 251 252 accompanied by cirrhosis before its onset, which lowers cholesterol levels before the onset of liver cancer.27, 28 253

254 Potential Underlying Mechanisms

255 The mechanisms underlying the associations between time-weighted RC with incident cancer 256 and cancer mortality have not been addressed before. Based on current studies regarding other lipid traits with cancer, several hypotheses may help explain the observed associations. First of all, altered 257 258 lipid metabolism is known to be a prominent metabolic alterations in cancer. Enhanced synthesis or uptake of lipids contributes to rapid cancer cell growth and tumor formation. Altered cholesterol 259 metabolism has been demonstrated to contribute to various aspects of carcinogenesis, such as 260 structural functions as components of cellular membranes,²⁹ controlling the communication between 261 cancer and immune cells within the cancer microenvironment,³⁰ activity of multiple signaling 262 pathways that are directly carcinogenic.^{20, 31} In addition, RC increases the production of reactive 263 oxygen species and induces inflammatory response, both of which has been considered to play a 264 critical role in the cancer development and progression.^{32, 33} Furthermore, lipid plays a major role in 265

regulation of the processes that initiate cell dissemination and metastasis formation.^{29, 34} Metastasis is the prime cause of cancer-related deaths, which could help explain the association between timeweighted RC with cancer mortality observed in the present study. Future studies are clearly needed to investigate the mechanisms underlying the effects of RC on cancer development.

270 *Clinical Implications and the future*

271 RC has been increasingly considered as a substantial risk factor for cardiometabolic diseases.³⁵ 272 Our findings add to the evidence that RC may also be a novel modifiable risk factor for new-onset 273 cancer and cancer-related mortality. One of strengthens of using family medicine cohort is that population in our study generally represents the least unwell patients that one would encounter in 274 275 daily clinical practice. Given the readily available and low cost of lipid testing, time-weighted RC has 276 the potential to achieve widespread clinical use with minimal interference of general medical practices.²⁰ Our findings suggest that including time-weighted RC in general medical assessments 277 could allow not only stratification of cardiometabolic risk, but also cancer risk. Future researches are 278 279 warranted to evaluate the effects of RC homeostasis management, such as behavioral or pharmacological intervention, on the prevention of cancer risk. 280

281 Limitations

282 First, given the retrospective nature of this study, there might be unmeasured and residual confounders which have not been accounted for. Nonetheless, we have adjusted for a range of well-283 established risk factors in the multivariable Cox regression analyses, which should account for most 284 potential confounding factors pertinent to our outcomes. Second, this study only included 285 286 participants from Hong Kong; therefore, the findings may not be generalizable to other populations. Future studies evaluating the association between RC and incident cancer among individuals of other 287 races are needed. In addition, causation relationship between RC and cancer using Mendelian 288 289 randomization in Eastern Asian should be further investigated to testify our result. Last, there is 290 inherent information bias due to under-coding, coding errors, and missing data. Nevertheless, previous studies have demonstrated good coding accuracy and data completeness in CDARS.^{9, 10} 291

292

293 Conclusions

Higher time-weighted RC was associated with increased risk of new-onset cancer and cancerrelated mortality amongst the general population. Time-weighted RC may be considered as a potential tool for cancer risk assessment and optimization of RC homeostasis may potentially help prevent cancer development.

298

299 Funding source

300 The authors received no funding for the research, authorship, and/or publication of this article.

301 Conflicts of Interest

G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo.
 No fees are directly received personally. He is a National Institute for Health and Care Research (NIHR)
 Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF,
 which has received funding from the European Union's Horizon 2020 research and innovation
 programme under grant agreement No 899871. The remaining authors have no disclosures to report.

307 Ethical approval statement

This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and complied with the Declaration of Helsinki.

311 Availability of data and materials

Data are not available, as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or nongovernmental organizations may apply for the access to data through the Hospital Authority's data sharing portal (https://www3.ha.org.hk/data).

317 Guarantor Statement

All authors approved the final version of the manuscript. GT is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

321 Author contributions

- 322 Data analysis: LL, NZ, JZ
- 323 Data review: LL, NZ, GT, JZ
- 324 Data acquisition: HHHP, BKHL, AKCW
- 325 Data interpretation: LL, NZ, CC, JZ, GT
- 326 Critical revision of manuscription: AKCW, CC, TL, GL, GT, JZ
- 327 Supervision: TL, GT, JZ
- 328 Manuscript writing: LL, NZ, GT, JZ
- 329 Manuscript revision: LL, NZ, AKCW, TL, GL, GT, JZ

330 Acknowledgements

- All the authors and colleagues from the Hospital Authority for providing de-identified clinical data are
- equally thanked for their contributions to this research. Special thanks to the support of the National
- 333 Natural Science Foundation of China (82170327, 82370332 to TL) and the Tianjin Key Medical
- 334 Discipline (Specialty) Construction Project (TJYXZDXK-029A).

335 References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
 and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249.
- 2. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2022;400(10352):563-591.
- 340 **3.** Hao B, Yu M, Sang C, Bi B and Chen J. Dyslipidemia and non-small cell lung cancer risk in Chinese 341 population: a case-control study. *Lipids Health Dis*. 2018;17(1):278.
- 342 4. Kuzu OF, Noory MA and Robertson GP. The Role of Cholesterol in Cancer. *Cancer Res.* 343 2016;76(8):2063-2070.
- 5. Wadström BN, Wulff AB, Pedersen KM, Jensen GB and Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. *Eur Heart J.* 2022;43(34):3258-3269.
- Huh JH, Roh E, Lee SJ, Ihm SH, Han KD and Kang JG. Remnant Cholesterol Is an Independent
 Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. *Diabetes Care*.
 2023;46(2):305-312.
- 350 7. Huang H, Xie J, Zeng Y, et al. Remnant Cholesterol Independently Predicts the Development of
 351 Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab.* 2023;108(11):2907-2915.
- Chan JSK, Satti DI, Lee YHA, et al. Temporal trends in cardiovascular burden among patients with
 prostate cancer receiving androgen deprivation therapy: a population-based cohort study. *Br J Cancer*.
 2023;128(12):2253-2260.
- Gao X, Zhang N, Lu L, et al. New-onset syncope in diabetic patients treated with sodium-glucose
 cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based
 cohort study. *Eur Heart J Cardiovasc Pharmacother*. 2023.
- 35810. Ren QW, Yu SY, Teng TK, et al. Statin associated lower cancer risk and related mortality in patients359with heart failure. *Eur Heart J.* 2021;42(32):3049-3059.
- 11. Zhou J, Wang X, Lee S, et al. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. *Gut*. 2021;70(10):2012-2013.
- Wu MZ, Chandramouli C, Wong PF, et al. Risk of sepsis and pneumonia in patients initiated on
 SGLT2 inhibitors and DPP-4 inhibitors. *Diabetes Metab.* 2022;48(6):101367.
- 13. Nordestgaard BG and Varbo A. Triglycerides and cardiovascular disease. Lancet.
 2014;384(9943):626-635.
- 14. Zhou J, Liu X, Chou OH, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2)
 inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. *Rheumatology (Oxford)*.
 2023;62(4):1501-1510.
- 15. Zhang N, Tse G and Liu T. Neutrophil-lymphocyte ratio in the immune checkpoint inhibitorsrelated atherosclerosis. *Eur Heart J.* 2021;42(22):2215.
- 16. Li X, Chan JSK, Guan B, et al. Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis. *Cardiovasc Diabetol*. 2022;21(1):229.
- 17. Navarese EP, Vine D, Proctor S, et al. Independent Causal Effect of Remnant Cholesterol on
- Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study. *Arterioscler Thromb Vasc Biol.* 2023;43(9):e373-e380.
- 18. Guan B, Wang A and Xu H. Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a mendelian randomization analysis. *Cardiovasc Diabetol*. 2023;22(1):207.

- In Zhang N, Jia Z, Gu T, et al. Associations between modifiable risk factors and frailty: a Mendelian
 randomisation study. *J Epidemiol Community Health*. 2023;77(12):782-790.
- 20. Chan JSK, Satti DI, Lee YHA, et al. Association Between Visit-to-Visit Lipid Variability and Incident
 Cancer: A Population-based Cohort Study. *Curr Probl Cardiol*. 2023;48(1):101421.
- 21. Chandler PD, Song Y, Lin J, et al. Lipid biomarkers and long-term risk of cancer in the Women's
 Health Study. Am J Clin Nutr. 2016;103(6):1397-1407.
- Swinnen JV, Brusselmans K and Verhoeven G. Increased lipogenesis in cancer cells: new players,
 novel targets. *Curr Opin Clin Nutr Metab Care*. 2006;9(4):358-365.
- Wadström BN, Pedersen KM, Wulff AB and Nordestgaard BG. Elevated remnant cholesterol,
 plasma triglycerides, and cardiovascular and non-cardiovascular mortality. *Eur Heart J*.
 2023;44(16):1432-1445.
- 24. Bonfiglio C, Leone CM, Silveira LVA, et al. Remnant cholesterol as a risk factor for cardiovascular,
 cancer or other causes mortality: A competing risks analysis. *Nutr Metab Cardiovasc Dis*.
 2020;30(11):2093-2102.
- 25. Teramoto K, Nadruz Junior W, Matsushita K, et al. Mid- to Late-Life Time-Averaged Cumulative
- Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. *Hypertension*. 2020;76(3):808-818.
- 395 26. Jiang Z, Shao F, Hu J, et al. Time-weighted blood pressure with cardiovascular risk among patients
 396 with or without diabetes. *Clin Cardiol*. 2024;47(1):e24213.
- 27. Tian Y, Wu Y, Qi M, et al. Associations of remnant cholesterol with cardiovascular and cancer mortality in a nationwide cohort. *Sci Bull (Beijing)*. 2024;69(4):526-534.
- 399 28. Iso H, Ikeda A, Inoue M, Sato S and Tsugane S. Serum cholesterol levels in relation to the incidence
 400 of cancer: the JPHC study cohorts. *Int J Cancer*. 2009;125(11):2679-2686.
- 29. Snaebjornsson MT, Janaki-Raman S and Schulze A. Greasing the Wheels of the Cancer Machine:
 The Role of Lipid Metabolism in Cancer. *Cell Metab.* 2020;31(1):62-76.
- 30. King RJ, Singh PK and Mehla K. The cholesterol pathway: impact on immunity and cancer. *Trends Immunol.* 2022;43(1):78-92.
- 405 **31.** Lyu J, Yang EJ and Shim JS. Cholesterol Trafficking: An Emerging Therapeutic Target for 406 Angiogenesis and Cancer. *Cells*. 2019;8(5).
- 407 **32.** Hayes JD, Dinkova-Kostova AT and Tew KD. Oxidative Stress in Cancer. *Cancer Cell*. 408 **2020;38(2):167-197**.
- 33. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted
 intervention. *Signal Transduct Target Ther*. 2021;6(1):263.
- 411 **34.** Baek AE, Yu YA, He S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast 412 cancer metastasis through its actions on immune cells. *Nat Commun*. 2017;8(1):864.
- 413 **35.** Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: 414 metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic 415 strategies-a consensus statement from the European Atherosclerosis Society. *Eur Heart J*. 416 **2021;42(47):4791-4806**.

Figures



Figure 1. The flow diagram of the study



Figure 2. Cumulative incidence curves between (A) baseline remnant cholesterol and (B) time-weighted remnant cholesterol with incidence of overall cancer.

Variable	Count (%)		Hazard ratio (95% CI)	P for interaction
Gender				
Male	29905 (39.7%)	H	1.10 [1.06-1.15]	0.266
Female	45437 (60.3%)	⊢ ∎→	1.07 [1.03-1.11]	
Age				
>65	32825 (43.6%)	H=-4	1.05 [1.02-1.09]	0.717
<65	42517 (56.4%)	⊢	1.07 [1.01-1.12]	
Cormorbidity				
Dyslipidemia (Yes)	1288 (1.7%)	⊢	1.48 [1.25-1.76]	<0.001
Dyslipidemia (No)	74054 (98.3%)	H	1.08 [1.05-1.11]	
Diabetes mellitus (Yes)	7889 (10.5%)	⊢	1.44 [1.34–1.55]	<0.001
Diabetes mellitus (No)	67453 (89.5%)	H=1	1.05 [1.02-1.09]	
Hypertension (Yes)	39026 (51.8%)	⊢ =-+	1.19 [1.15-1.23]	<0.001
Hypertension (No)	36316 (48.2%)	⊢	1.01 [0.96-1.05]	
Stroke/TIA (Yes)	508 (0.7%)	⊢ ≈ >	1.27 [0.96-1.68]	0.261
Stroke/TIA (No)	74834 (99.3%)	H=-1	1.09 [1.06-1.12]	
IHD (Yes)	1516 (2.0%)		1.29 [1.07–1.54]	0.028
IHD (No)	73826 (98.0%)	H=1	1.08 [1.05-1.12]	
Liver diseases (Yes)	269 (0.4%)	⊢ ⇒	1.45 [1.09-1.91]	0.033
Liver diseases (No)	75073 (99.6%)	H=H	1.09 [1.06-1.12]	
Renal diseases (Yes)	105 (0.1%)	<→	1.13 [0.50-2.59]	0.939
Renal diseases (No)	75237 (99.9%)	H=H	1.09 [1.06-1.12]	
Medication use				
ACEI/ARB (Yes)	8890 (11.8%)	⊢	1.22 [1.14-1.30]	<0.001
ACEI/ARB (No)	66452 (88.2%)	⊢ ⊷⊣	1.07 [1.03-1.10]	
Antiplatelets (Yes)	7921 (10.5%)	⊢	1.14 [1.07-1.22]	0.026
Antiplatelets (No)	67421 (89.5%)	H=-1	1.07 [1.04-1.10]	
Lipid lowering drugs (Yes)	7021 (9.3%)	+ - +	1.16 [1.07-1.26]	0.061
Lipid lowering drugs (No)	68321 (90.7%)	H=-1	1.08 [1.05-1.11]	
Statins and fibrates (Yes)	8460 (11.2%)		1.15 [1.07-1.24]	0.074
Statins and fibrates (No)	66882 (88.8%)	⊢ ∎-1	1.08 [1.04-1.11]	
Beta blockers (Yes)	15006 (19.9%)		1.12 [1.06-1.19]	0.294
Beta blockers (No)	60336 (80.1%)	⊢ ∎-1	1.08 [1.04-1.11]	
Non-steroidal anti-inflammatory drugs (Yes)	7594 (10.1%)		1.14 [1.07-1.22]	0.036
Non-steroidal anti-inflammatory drugs (No)	67748 (89.9%)	H=1	1.07 [1.04-1.10]	
Antidiabetic drugs (Yes)	15121 (20.1%)		1.05 [1.00-1.12]	0.257
Antidiabetic drugs (No)	60221 (79.9%)	H=	1.09 [1.06-1.13]	
		0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 Hazard ratio (95% CI)		



Table 1. Baseline and clinical characteristics of family medicine patients stratified by quantiles of remnant cholesterol.

SD: standard deviation: RC: remnant cholesterol: TIA: transient ischaemic attack: ACEI: angiotensin-converting enzyme inhibitors: ARB: angiotensin II receptor blockers. MDRD: modification of diet in renal disease.

Characteristics	Baseline RC quantiles Mean(SD);N or Count(%)					Time-weighted RC quantiles Mean(SD);N or Count(%)						
	Q1 <0.44 mmol/L (N=18779)	Q2 0.44-0.64 mmol/L (N=18964)	Q3 0.64-0.96 mmol/L (N=18838)	Q4 >0.96 mmol/L (N=18761)	Total (N=75342)	P value	Q1 <0.53 mmol/L (N=18894)	Q2 0.53-0.70 mmol/L (N=18820)	Q3 0.70-0.93 mmol/L (N=18757)	Q4 <0.93 mmol/L (N=18871)	Total (N=75342)	P value
Demographic												
Sex (Male)	7697 (41.0)	7519 (39.6)	7245 (38.5)	7444 (39.7)	29905 (39.7)	<0.00 1	7896 (41.8)	7363 (39.1)	7120 (38.0)	7526 (39.9)	29905 (39.7)	<0.00 1
Baseline age, years	61.4 (49.8,71.2)	62.9 (51.9,71.6)	62.9 (52.2,71.3)	62.6 (52.0,71.3)	62.5 (51.5,71.4)	<0.00 1	62.9 (51.5,71.7)	61.4 (51.2,70.1)	61.3 (51.1,70.2)	64.5 (52.2,73.5)	62.5 (51.5,71.4)	<0.00 1
Age larger than 65	7891 (42.0)	8400 (44.3)	8327 (44.2)	8207 (43.7)	32825 (43.6)	<0.00 1	8413 (44.5)	7616 (40.5)	7613 (40.6)	9183 (48.7)	32825 (43.6)	<0.00 1
Comorbidity												
Charlson's standard comorbidity index	2.0 (0.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	<0.00 1	2.0 (1.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	2.0 (1.0,3.0)	<0.00 1
Dyslipidemia	188 (1.0)	280 (1.5)	348 (1.8)	472 (2.5)	1288 (1.7)	<0.00 1	259 (1.4)	279 (1.5)	368 (2.0)	382 (2.0)	1288 (1.7)	<0.00 1
Diabetes mellitus	1395 (7.4)	1638 (8.6)	2064 (11.0)	2792 (14.9)	7889 (10.5)	<0.00 1	1546 (8.2)	1834 (9.7)	2222 (11.8)	2287 (12.1)	7889 (10.5)	<0.00 1
Hypertension	8800 (46.9)	9815 (51.8)	10104 (53.6)	10307 (54.9)	39026 (51.8)	<0.00 1	9533 (50.5)	9735 (51.7)	9952 (53.1)	9806 (52.0)	39026 (51.8)	<0.00 1
Heart failure	557 (3.0)	652 (3.4)	784 (4.2)	939 (5.0)	2932 (3.9)	<0.00 1	591 (3.1)	592 (3.1)	735 (3.9)	1014 (5.4)	2932 (3.9)	<0.00 1
Atrial fibrillation/Atrial flutter Stroke/TIA	116 (0.6) 92 (0.5)	120 (0.6) 135 (0.7)	106 (0.6) 139 (0.7)	104 (0.6) 142 (0.8)	446 (0.6) 508 (0.7)	0.688 0.005	122 (0.6) 128 (0.7)	106 (0.6) 113 (0.6)	102 (0.5) 121 (0.6)	116 (0.6) 146 (0.8)	446 (0.6) 508 (0.7)	0.553 0.207
Ischemic heart disease	322 (1.7)	362 (1.9)	395 (2.1)	437 (2.3)	1516 (2.0)	<0.00 1	345 (1.8)	407 (2.2)	391 (2.1)	373 (2.0)	1516 (2.0)	0.107
Liver diseases Renal diseases Medication use	87 (0.5) 26 (0.1)	68 (0.4) 18 (0.1)	56 (0.3) 31 (0.2)	58 (0.3) 30 (0.2)	269 (0.4) 105 (0.1)	0.028 0.249	75 (0.4) 24 (0.1)	78 (0.4) 17 (0.1)	65 (0.3) 29 (0.2)	51 (0.3) 35 (0.2)	269 (0.4) 105 (0.1)	0.084 0.084
ACEI/ARB	1755 (9.3)	2100 (11.1)	2282 (12.1)	2753 (14.7)	8890 (11.8)	<0.00 1	1851 (9.8)	2058 (10.9)	2319 (12.4)	2662 (14.1)	8890 (11.8)	<0.00 1
Antiplatelets	1662 (8.9)	1966 (10.4)	2051 (10.9)	2242 (12.0)	7921 (10.5)	<0.00 1	1827 (9.7)	1778 (9.4)	1925 (10.3)	2391 (12.7)	7921 (10.5)	<0.00 1
Lipid-lowering drugs	1200 (6.4)	1624 (8.6)	1840 (9.8)	2357 (12.6)	7021 (9.3)	<0.00 1	1372 (7.3)	1687 (9.0)	1897 (10.1)	2065 (10.9)	7021 (9.3)	<0.00 1
Statins and fibrates	1353 (7.2)	1825 (9.6)	2207 (11.7)	3075 (16.4)	8460 (11.2)	<0.00 1	1506 (8.0)	1893 (10.1)	2348 (12.5)	2713 (14.4)	8460 (11.2)	<0.00 1
Beta blockers	2792 (14.9)	3503 (18.5)	4042 (21.5)	4669 (24.9)	15006 (19.9)	<0.00 1	3220 (17.0)	3570 (19.0)	4064 (21.7)	4152 (22.0)	15006 (19.9)	<0.00 1
Non-steroidal anti-inflammatory drugs	1604 (8.5)	1890 (10.0)	1964 (10.4)	2136 (11.4)	7594 (10.1)	<0.00 1	1759 (9.3)	1706 (9.1)	1830 (9.8)	2299 (12.2)	7594 (10.1)	<0.00 1
Anti-diabetic drugs	2860 (15.2)	3483 (18.4)	3996 (21.2)	4782 (25.5)	15121 (20.1)	<0.00 1	3104 (16.4)	3329 (17.7)	3922 (20.9)	4766 (25.3)	15121 (20.1)	<0.00 1
Calculated biomarkers												
eGFR (MDRD), mL/min/1.73m2	75.0 (64.4,86.4)	72.9 (62.4,84.6)	72.1 (61.5,83.9)	71.1 (60.2,82.5)	72.7 (61.9,84.3)	<0.00 1	73.4 (62.8,85.1)	73.6 (63.1,84.9)	73.1 (62.5,84.4)	70.8 (59.3,82.6)	72.7 (61.9,84.3)	<0.00 1
Neutrophil-to-lymphocyte ratio	2.3 (1.7,3.7)	2.3 (1.7,3.6)	2.2 (1.6,3.5)	2.2 (1.6,3.5)	2.2 (1.6,3.6)	0.001	2.3 (1.6,3.6)	2.2 (1.6,3.4)	2.2 (1.6,3.4)	2.3 (1.6,3.8)	2.2 (1.6,3.6)	0.004

Triglyceride-glucose index	6.7 (6.4,7.0)	7.1 (6.9,7.3)	7.4 (7.2,7.7)	7.8 (7.5,8.2)	7.3 (6.9,7.8)	<0.00 1	7.1 (6.7,7.5)	7.2 (6.8,7.6)	7.4 (7.0,7.8)	7.5 (7.1,8.0)	7.3 (6.9,7.8)	<0.00 1
kidney and liver function						-						-
Creatinine, umol/L	81.0 (70.0,96.0)	83.0 (72.0,97.0)	84.0 (72.0,98.0)	85.0 (73.0,100.0)	84.0 (72.0,98.0)	<0.00 1	83.0 (72.0,98.0)	83.0 (72.0,96.0)	83.0 (71.0,97.0)	85.0 (73.0,100.0)	84.0 (72.0,98.0)	<0.00 1
Alkaline phosphatase, U/L	74.0 (60.0,90.0)	77.0 (63.0,94.0)	78.0 (64.0,95.0)	80.0 (66.0,97.0)	78.0 (63.0,95.0)	<0.00 1	76.0 (62.0,93.0)	77.0 (63.0,93.0)	78.0 (64.0,95.0)	79.0 (65.0,97.0)	78.0 (63.0,95.0)	<0.00 1
Aspartate transaminase, U/L	19.0 (15.0,27.0)	20.0 (15.0,28.0)	21.0 (16.0,30.0)	22.0 (17.0,31.0)	21.0 (16.0,29.0)	<0.00 1	20.0 (15.0,27.0)	21.0 (16.0,29.0)	21.0 (16.0,30.0)	21.0 (16.0,30.0)	21.0 (16.0,29.0)	<0.00 1
Alanine transaminase, U/L	19.0 (14.0.28.0)	20.0 (15.0.29.0)	22.0 (15.0.31.0)	23.0 (16.0.34.0)	21.0 (15.0.31.0)	<0.00 1	21.0 (15.0.29.0)	21.0 (15.0.31.0)	22.0 (16.0.32.0)	21.0 (15.0.31.0)	21.0 (15.0.31.0)	<0.00 1
Bilirubin, umol/L Glucose and blood pressure profiles	10.0 (7.0,13.0)	9.6 (7.0,12.9)	9.5 (7.0,13.0)	9.2 (7.0,12.4)	9.5 (7.0,13.0)	0.002	9.9 (7.0,13.0)	9.9 (7.0,13.0)	9.3 (7.0,12.7)	9.3 (7.0,12.6)	9.5 (7.0,13.0)	0.001
Systolic blood pressure, mmHg	136.0 (120.0,150.0)	139.0 (125.0,153.0)	140.0 (127.0,153.0)	140.0 (127.0,153.0)	139.0 (125.0,152.0)	<0.00 1	138.0 (123.0,152.0)	139.0 (125.0,152.0)	139.0 (126.0,152.0)	139.0 (125.0,153.0)	139.0 (125.0,152.0)	<0.00 1
SD of systolic blood pressure	12.9 (9.9,16.1)	13.2 (10.4,16.6)	13.3 (10.6,16.6)	13.5 (10.7,16.8)	13.2 (10.4,16.5)	<0.00 1	13.1 (10.3,16.4)	13.2 (10.5,16.4)	13.3 (10.5,16.4)	13.3 (10.3,16.9)	13.2 (10.4,16.5)	0.001
Diastolic blood pressure, mmHg	75.0 (68.0,82.0)	76.0 (69.0,84.0)	77.0 (69.0,84.0)	77.0 (70.0,85.0)	76.0 (69.0,84.0)	<0.00 1	76.0 (68.0,83.0)	76.0 (69.0,84.0)	77.0 (69.0,84.0)	76.0 (68.0,84.0)	76.0 (69.0,84.0)	<0.00 1
SD of diastolic blood pressure	7.5 (6.0,9.2)	7.8 (6.2,9.5)	7.8 (6.3,9.5)	7.9 (6.4,9.6)	7.8 (6.2,9.5)	<0.00 1	7.7 (6.1,9.4)	7.8 (6.3,9.4)	7.8 (6.3,9.5)	7.8 (6.1,9.6)	7.8 (6.2,9.5)	0.002
HbA1C, %	7.0 (6.2,8.0)	7.1 (6.3,8.1)	7.1 (6.4,8.2)	7.4 (6.5,8.5)	7.2 (6.3,8.3)	<0.00 1	7.1 (6.3,8.2)	7.1 (6.3,8.3)	7.2 (6.4,8.2)	7.2 (6.4,8.4)	7.2 (6.3,8.3)	0.003
SD of HbA1C	0.5 (0.3,0.9)	0.5 (0.3,0.9)	0.5 (0.3,0.9)	0.6 (0.3,1.0)	0.5 (0.3,0.9)	<0.00 1	0.5 (0.3,0.9)	0.5 (0.3,0.9)	0.5 (0.3,0.9)	0.6 (0.3,1.0)	0.5 (0.3,0.9)	0.001
Time weighted mean HbA1C, %	7.2 (6.7,7.8)	7.2 (6.7,7.8)	7.2 (6.7,7.8)	7.2 (6.7,7.8)	7.2 (6.7,7.8)	0.077	7.2 (6.7,7.8)	7.2 (6.7,7.8)	7.3 (6.8,7.8)	7.3 (6.7,7.8)	7.2 (6.7,7.8)	0.004
Fasting glucose, mmol/L	5.6 (5.0,7.2)	5.8 (5.1,7.5)	6.0 (5.2,7.8)	6.2 (5.3,8.1)	5.9 (5.2,7.7)	<0.00 1	5.8 (5.1,7.5)	5.9 (5.1,7.7)	6.0 (5.2,7.8)	6.0 (5.2,7.7)	5.9 (5.2,7.7)	<0.00 1
SD of fasting glucose	0.6 (0.3,1.6)	0.7 (0.3,1.6)	0.7 (0.3,1.7)	0.8 (0.3,1.7)	0.7 (0.3,1.6)	<0.00 1	0.7 (0.3,1.7)	0.7 (0.3,1.6)	0.7 (0.3,1.6)	0.7 (0.3,1.7)	0.7 (0.3,1.6)	0.005
Time weighted mean fasting glucose, mmol/L	6.7 (5.6,7.9)	6.8 (5.6,7.9)	6.9 (5.7,8.1)	7.0 (5.9,8.1)	6.8 (5.7,8.0)	<0.00 1	6.8 (5.7,8.0)	6.8 (5.6,7.9)	6.9 (5.8,8.0)	7.0 (6.0,8.2)	6.8 (5.7,8.0)	<0.00 1
Lipid profiles and variability												
Triglyceride, mmol/L	0.8 (0.7,0.9)	1.2 (1.1,1.3)	1.7 (1.5,1.9)	2.5 (2.1,3.1)	1.4 (1.0,1.9)	<0.00 1	1.1 (0.8,1.5)	1.3 (0.9,1.7)	1.5 (1.1,2.1)	1.7 (1.2,2.5)	1.4 (1.0,1.9)	<0.00 1
SD of triglyceride	0.2 (0.1,0.3)	0.3 (0.2,0.4)	0.4 (0.3,0.5)	0.6 (0.4,0.9)	0.3 (0.2,0.5)	<0.00 1	0.2 (0.2,0.4)	0.3 (0.2,0.4)	0.4 (0.3,0.6)	0.5 (0.3,0.8)	0.3 (0.2,0.5)	<0.00 1
Time weighted mean triglyceride, mmol/L	1.2 (1.0,1.4)	1.3 (1.2,1.6)	1.5 (1.3,1.7)	1.7 (1.5,2.1)	1.4 (1.2,1.7)	<0.00 1	1.2 (1.1,1.4)	1.4 (1.2,1.5)	1.6 (1.3,1.8)	1.8 (1.4,2.2)	1.4 (1.2,1.7)	<0.00 1
Low-density lipoprotein, mmol/L	2.9 (2.4,3.5)	3.2 (2.6,3.8)	3.3 (2.7,3.9)	3.0 (2.4,3.7)	3.1 (2.5,3.7)	<0.00 1	3.0 (2.5,3.6)	3.1 (2.6,3.7)	3.2 (2.6,3.8)	3.1 (2.5,3.7)	3.1 (2.5,3.7)	<0.00 1
SD of low-density lipoprotein	0.5 (0.3,0.7)	0.5 (0.3,0.8)	0.6 (0.4,0.8)	0.6 (0.4,0.8)	0.6 (0.3,0.8)	<0.00 1	0.5 (0.3,0.7)	0.6 (0.4,0.8)	0.6 (0.4,0.8)	0.6 (0.3,0.8)	0.6 (0.3,0.8)	<0.00 1
Time weighted mean low-density lipoprotein, mmol/L	2.7 (2.4,3.0)	2.7 (2.4,3.0)	2.7 (2.4,3.0)	2.7 (2.4,3.0)	2.7 (2.4,3.0)	<0.00 1	2.7 (2.5,3.1)	2.7 (2.4,3.0)	2.7 (2.4,3.0)	2.6 (2.3,3.0)	2.7 (2.4,3.0)	<0.00 1
High-density lipoprotein, mmol/L	1.5 (1.3,1.8)	1.4 (1.1,1.6)	1.2 (1.1,1.4)	1.1 (1.0,1.3)	1.3 (1.1,1.6)	<0.00 1	1.4 (1.1,1.7)	1.3 (1.1,1.6)	1.3 (1.1,1.5)	1.2 (1.0,1.4)	1.3 (1.1,1.6)	<0.00 1
SD of high-density lipoprotein	0.2 (0.1,0.2)	0.1 (0.1,0.2)	0.1 (0.1,0.2)	0.1 (0.1,0.2)	0.1 (0.1,0.2)	<0.00 1	0.2 (0.1,0.2)	0.2 (0.1,0.2)	0.1 (0.1,0.2)	0.1 (0.1,0.2)	0.1 (0.1,0.2)	<0.00 1
Time weighted mean high-density lipoprotein, mmol/L	1.4 (1.3,1.6)	1.3 (1.2,1.5)	1.3 (1.2,1.4)	1.2 (1.1,1.4)	1.3 (1.2,1.5)	<0.00 1	1.4 (1.3,1.6)	1.3 (1.2,1.5)	1.3 (1.2,1.4)	1.2 (1.1,1.3)	1.3 (1.2,1.5)	<0.00 1

Total cholesterol, mmol/L	4.8 (4.2,5.5)	5.1 (4.5,5.8)	5.3 (4.7,6.0)	5.6 (5.0,6.4)	5.2 (4.6,5.9)	<0.00 1	5.1 (4.5,5.8)	5.2 (4.6,5.9)	5.3 (4.7,6.0)	5.4 (4.7,6.1)	5.2 (4.6,5.9)	<0.00 1
SD of total cholesterol	0.5 (0.3,0.8)	0.6 (0.4,0.8)	0.7 (0.4,0.9)	0.8 (0.5,1.0)	0.6 (0.4,0.9)	<0.00 1	0.6 (0.4,0.8)	0.6 (0.4,0.9)	0.7 (0.4,0.9)	0.6 (0.4,0.9)	0.6 (0.4,0.9)	<0.00 1
Time weighted mean total cholesterol, mmol/L Remnant cholesterol tests and variability	4.7 (4.4,5.1)	4.7 (4.4,5.1)	4.8 (4.4,5.1)	4.8 (4.5,5.2)	4.7 (4.4,5.1)	<0.00 1	4.6 (4.2,4.9)	4.7 (4.4,5.0)	4.8 (4.5,5.1)	5.0 (4.7,5.4)	4.7 (4.4,5.1)	<0.00 1
Remnant cholesterol, mmol/L	0.3 (0.3,0.4)	0.5 (0.5,0.6)	0.8 (0.7,0.9)	1.3 (1.1,1.6)	0.6 (0.4,1.0)	<0.00 1	0.5 (0.4,0.7)	0.6 (0.4,0.8)	0.7 (0.5,1.0)	0.8 (0.5,1.3)	0.6 (0.4,1.0)	<0.00 1
Time weighted remnant cholesterol, mmol/L	0.6 (0.4,0.8)	0.6 (0.5,0.8)	0.7 (0.6,0.9)	0.9 (0.7,1.1)	0.7 (0.5,0.9)	<0.00 1	0.4 (0.3,0.5)	0.6 (0.6,0.7)	0.8 (0.7,0.9)	1.2 (1.0,1.8)	0.7 (0.5,0.9)	<0.00 1

Table 2. Results of multivariate Cox analyses between baseline RC and time-weighted RC with outcomes.

* for $p \le 0.05$, ** for $p \le 0.01$, *** for $p \le 0.001$, Abbreviations: AMDRD, abbreviated modification of diet in renal disease; RC, remnant cholesterol; HR, hazard ratio.

Models	Effects on RC	Effects of time-weighted RC
Madel 4. Deine editorted for democratic	afik [95% CI];P value	afic [95% CI];P value
Model 1: Being adjusted for demographics	4 07[4 02 4 44] 0 0002***	1 02[0 00 1 05] 0 1204
Overall cancer		1.02[0.99-1.05];0.1204
Cancer mortality	1.11[1.05-1.16];0.0001***	1.24[1.21-1.27];<0.0001***
Lung cancer	1.10[1.01-1.19];0.0214*	1.13[1.07-1.19];<0.0001***
Gastrointestinal cancer	1.04[0.98-1.10];0.2246	1.03[0.99-1.07];0.1976
Breast cancer	1.18[1.08-1.28];0.0001***	0.95[0.87-1.03];0.2110
Ovarian cancer	1.15[0.86-1.55];0.3386	1.20[0.98-1.48];0.0778
Prostate cancer	0.94[0.83-1.08];0.3856	0.96[0.88-1.05];0.3372
Genitourinary cancer	1.03[0.95-1.11];0.4792	0.97[0.91-1.03];0.2569
Colorectal cancer	1.02[0.95-1.11];0.5595	0.98[0.93-1.04];0.5266
Pancreas cancer	1.19[1.03-1.38];0.0188*	0.99[0.84-1.15];0.8517
Bladder cancer	1.10[0.95-1.28];0.1864	0.91[0.81-1.03];0.1370
Liver cancer	0.81[0.68-0.97];0.0211*	1.10[1.00-1.21];0.0555
Model 2: Being adjusted for demographics, o	comorbidities, medications	
v@vepratldGantesc.//doi.org/10.1101/2024.03.07.2430390	3; this version poste 054 the 812 12 09 10 000 of the propriet	1.04[1.01-1.07];0.0045**
Cancer mortality It is made available under a	CC-BY-NC 4.0 Intelnetional Octave and a set as a	1.27[1.24-1.31];<0.0001***
Lung cancer	1.07[0.98-1.17];0.1078	1.15[1.09-1.21];<0.0001***
Gastrointestinal cancer	0.99[0.94-1.06];0.8638	1.05[1.01-1.09];0.0229*
Breast cancer	1.14[1.06-1.23];0.0008***	0.95[0.87-1.04];0.2793
Ovarian cancer	1.12[0.86-1.46];0.4052	1.18[0.96-1.46];0.1094
Prostate cancer	0.86[0.74-0.99];0.0356*	1.00[0.91-1.09];0.9494
Genitourinary cancer	1.00[0.92-1.09];0.9848	0.99[0.94-1.06];0.8574
Colorectal cancer	0.97[0.90-1.06]:0.5423	1.00[0.94-1.06]:0.9656
Pancreas cancer	1.20[1.02-1.42]:0.0287*	1.02[0.87-1.19]:0.8202
Bladder cancer	1.05[0.89-1.24];0.5406	0.96[0.85-1.09]:0.5538
Liver cancer	0.77[0.64-0.93]:0.0061**	1.13[1.02-1.25]:0.0172*
Model 3: Being adjusted for demographics, o	comorbidities, medications, AMDRD, calculated biomarkers	blood pressure
Overall Cancer	1.02[0.93-1.11]:0.6660	1.26[1.20-1.32]:<0.0001***
Cancer mortality	0.97[0.86-1.10]:0.6764	1 49[1 42-1 57]:<0 0001***
	1 06[0 88-1 27]:0 5480	1 36[1 23-1 49]:<0 0001***
Gastrointestinal cancer	0 93[0 81-1 07]:0 3269	1 31[1 22-1 41]:<0 0001***
Breast cancer	0.88[0.69-1.13]:0.3214	1.06[0.88-1.26]:0.5458
Ovarian cancer		1.41[0.01.2.10].0.1267
Prostate cancer		1.41[0.91-2.19],0.1207
	1.05[0.77-1.38],0.8209	1.11[0.92-1.35],0.2782
Genicourinary cancer		
		1.25[1.13-1.38];<0.0001
Pancreas cancer	1.26[0.91-1.75];0.1706	1.44[1.15-1.81];0.0016**
Bladder cancer		1.11[0.91-1.35];0.3218
Liver cancer	0.42[0.24-0.72];0.0016**	1.33[1.11-1.59];0.0022**
Model 4: Being adjusted for demographics, or glucose and lipid profiles	comorbidities, medications, AMDRD, calculated biomarkers	, baseline and time-weighted blood pressure,
Querall Cancer	1 04[0 82 1 21]-0 7677	1 41[1 26 1 57].~0 0001***
	1.04[0.62-1.31],0.7077	1.41[1.20-1.37], < 0.0001
	0.85[0.01-1.17];0.3153	$1.02[1.43 - 1.85], < 0.0001^{+++}$
Lung Cancer		1.00[1.28-2.00];<0.0001***
Gastrointestinal cancer		1.39[1.18-1.64];0.0001***
Breast cancer	1.50[0.89-2.52];0.1259	1.12[0./4-1./0];0.5904
Ovarian cancer	1.46[0.35-6.04];0.5990	2.71[1.23-5.95];0.0133*
Prostate cancer	0.98[0.49-1.93];0.9440	1.27[0.91-1.77];0.1682
Genitourinary cancer	0.91[0.54-1.54];0.7375	1.27[1.00-1.61];0.0483*
Colorectal cancer	1.23[0.84-1.82];0.2912	1.47[1.21-1.78];0.0001***
Pancreas cancer	0.47[0.13-1.73];0.2564	0.45[0.09-2.39];0.3512
Bladder cancer	1 04[0 38-2 84]•0 9388	0 73[0 31-1 73]•0 4705

Liver cancer 0.79[0.30-2.07];0.6259 0.86[0.38-1.95];0.7213
--